NCT04214873CompletedNot Applicable
A Pilot Study to Evaluate the Effectiveness of the PiQo4 Picosecond Laser (PSL) System for Reduction of Infra-orbital Pigmentation
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Focus Medical, LLC
- Enrollment
- 8
- Locations
- 2
- Primary Endpoint
- Change in POH severity
Study Overview
Brief Summary
A total of 10 healthy subjects at a single site, aged 18-65 years old and Fitzpatrick skin type I-IV with mild to moderate infra-orbital hyperpigmentation on the background of epidermal and/or dermal pigmentation that wish to improve their POH
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 65 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Females or males
- •Fitzpatrick skin types I-IV
- •POH on the background of epidermal and/or dermal pigmentation
- •POH severity - mild to moderate
- •Able to read, understand and provide written Informed Consent.
- •Able and willing to comply with the treatment/follow-up schedule and post treatment care
- •Agreed to use the same facial skin care products during the clinical trial period (including the follow-up period)
- •Agreed to the prohibition of the use of local/systemic corticosteroids or retinoids and other local/systemic lightening medications, and willing to abide by such instructions
- •Agreed to the daily use of an over SPF 50 sunblock on their face during the clinical trial period (including the follow-up period), and willing to abide by such instructions
- •Agreed to have their face photographed and willingness to allow Focus Medical (the study Sponsor) and Lumenis and the investigators to use de-identified photographs of the treated area for presentation and publication purposes
- •Women of childrearing potential (not postmenopausal [no menstrual cycle for at least 12 months], without an uterus and/or both ovaries, or has had a bilateral tubal ligation)
- •*(In case of women of childbearing potential) Tested negative in the pregnancy test and agreed to use birth control measures during the clinical trial period including use of contraceptives (see list below) IUD, Double-Barrier Method, Vasectomized Partner, No Heterosexual Intercourse, etc
- •Agreed not to undergo any other procedure on their face during their participation in the clinical trial
Exclusion Criteria
- •Pregnant or breastfeeding
- •Inability to comply with all study protocols and regulations
- •Participation in a study of another device or drug
- •Heavy smokers and/or drinkers (those who smoke 25 or more cigarettes a day and/or ⩾8 drinks a week for women, and ⩾15 for men)
- •Application of any energy device treatment to the infraorbital region within 3 months
- •Application of any dermal filler to the infraorbital region within 6 months
- •Facial resurfacing, deep chemical peels, or taking oral retinoids within 6 months
- •Microdermabrasion (light or medium skin peel) treatment within 30 days
- •Chemical peel, systemic steroids, non-ablative laser, light, or radiofrequency treatment within 3 months
- •Use of topical lightening agents or retinoids within 14 days
- •Any planned surgical intervention to the face for the duration of the trial
- •Use of Latisse, Revitalash, or other lash enhancement stimulators as well as Bimatoprost in the previous 1 month
- •Presence of open wounds, lesions, or scarring in the area
- •Very thin skin (skin that tears, bruises, or breaks easily)
- •Suffering from current or history of significant skin conditions in the treated area that could interfere with the evaluation (i.e. infection, dermatitis, or rash on their face) or requires the use of interfering topical or systemic therapy.
- •Excessively tanned in areas to be treated or unable/unlikely to refrain from tanning during the study.
- •Having a history of diseases stimulated by heat, such as recurrent Herpes Simplex (HSV, HZO) in the treated area, unless treatment is conducted following a prophylactic regimen
- •History of keloid scarring, hypertrophic scarring, or of abnormal wound healing.
- •History of connective tissue diseases such as systemic lupus erythematosus or scleroderma
- •History of post inflammatory pigmentary disorders, particularly a tendency for hyper- or hypo-pigmentation.
- •History of cutaneous photosensitization, porphyria, and hypersensitivity to porphyrins or photodermatosis.
- •Has used photosensitizing drugs (e.g., Declomycin, sulfa antibiotics, phenothiazines, etc.) within a timeframe where photosensitization from these drugs may still be present
- •History of skin cancer
- •Change of contraceptives dosing in the past 3 months
- •Medical disorders such as thyroid or kidney diseases
- •Significant concurrent illness or any disease state that in the opinion of the Investigator would interfere with the treatment or healing process
- •As per the Investigator's discretion, any physical or mental condition which might make it unsafe for the subject to participate in this study
Outcomes
Primary Outcomes
Change in POH severity
Time Frame: 3 month follow up
POH improvement of at least 1 point evaluated by the investigator at the 3-month follow up compared to baseline using the POH severity in comparison to surrounding skin scale where score of between 0 and 4 will be assigned (0-Normal (Skin color comparable to other facial skin areas); 1- Trace (Faint pigmentation of infraorbital fold (bilateral)); 2- Mild (Pigmentation more pronounced); 3- Moderate (Deep dark colour, all four lids involved): ; 4 - Marked (Grade 3 + pigmentation spreading beyond infraorbital fold)
Secondary Outcomes
- Aesthetic improvement(3 month follow up)
Investigators
Study Sites (2)
Loading locations...
Similar Trials
Not yet recruiting
Not Applicable
A pilot study to assess the various dermatoses associated with usage of facial mask in COVID-19 PandemicCTRI/2021/02/030878ishi Nagaria364
Completed
Not Applicable
Single arm pilot study to evaluate the effectiveness of oolong tea in upper gastrointestinal endoscopyPerson planning screening upper gastrointestinal endoscopyJPRN-UMIN000040070Osaka Center for Cancer and Cardiovascular Disease Prevention5
Completed
Phase 1
PEP005 Gel - Biological Effects in Actinic Keratosis Assessed by HistologyActinic KeratosisNCT01387711LEO Pharma27
Completed
Phase 1
PEP005 Gel - Biological Effects in Actinic Keratosis Assessed by Reflectance Confocal MicroscopyActinic KeratosisNCT01449513LEO Pharma24
Unknown
Phase 1
Study Will Assess Skin Irritation and Sensitization for HP-1050 PatchCumulative Irritation and SensitizationNCT04624867Noven Pharmaceuticals, Inc.240